CA2319730A1 - Antagonistes de bradykinine - Google Patents

Antagonistes de bradykinine Download PDF

Info

Publication number
CA2319730A1
CA2319730A1 CA002319730A CA2319730A CA2319730A1 CA 2319730 A1 CA2319730 A1 CA 2319730A1 CA 002319730 A CA002319730 A CA 002319730A CA 2319730 A CA2319730 A CA 2319730A CA 2319730 A1 CA2319730 A1 CA 2319730A1
Authority
CA
Canada
Prior art keywords
ligand
linker
alkyl
substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002319730A
Other languages
English (en)
Inventor
Burton G. Christensen
Maya Natarajan
John H. Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2319730A1 publication Critical patent/CA2319730A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne de nouveaux composés à liaisons multiples qui sont des antagonistes de bradykinine. Ces composés à liaisons multiples comprennent 2 à 10 ligands, fixés par covalence à un ou plusieurs segments de liaison, chacun de ces ligands étant, indépendamment des autres, un antagoniste de bradykinine. Les composés à liaisons multiples de cette invention sont utiles pour prévenir et traiter les maladies comme le cancer, l'algie, l'état de choc, l'asthme, la rhinite, l'arthrite, l'affection intestinale inflammatoire, et analogues.
CA002319730A 1998-06-08 1999-06-07 Antagonistes de bradykinine Abandoned CA2319730A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8846698P 1998-06-08 1998-06-08
US60/088,466 1998-06-08
US9293898P 1998-07-15 1998-07-15
US60/092,938 1998-07-15
US12575199P 1999-03-23 1999-03-23
US60/125,751 1999-03-23
PCT/US1999/012674 WO1999064039A1 (fr) 1998-06-08 1999-06-07 Antagonistes de bradykinine

Publications (1)

Publication Number Publication Date
CA2319730A1 true CA2319730A1 (fr) 1999-12-16

Family

ID=27375976

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002319730A Abandoned CA2319730A1 (fr) 1998-06-08 1999-06-07 Antagonistes de bradykinine

Country Status (5)

Country Link
EP (1) EP1085895A1 (fr)
JP (1) JP2002517461A (fr)
AU (1) AU4335299A (fr)
CA (1) CA2319730A1 (fr)
WO (1) WO1999064039A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932228B2 (en) 2004-08-19 2011-04-26 Societe de Commercialisation des Produits de la Recherche Applique Socpra Sciences Sante et Humaines S.E.C. Method of treating bone or prostate cancer with selective bradykinin B1 receptor antagonists
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
AR113839A1 (es) 2017-11-24 2020-06-17 Pharvaris B V Antagonistas del receptor b2 de bradiquinina
UY38706A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
AR118983A1 (es) 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
RS65427B1 (sr) 2021-08-05 2024-05-31 Pharvaris Gmbh Kompozicija na bazi lipida za oralnu primenu antagonista receptora bradikinina b2
WO2023180575A1 (fr) 2022-03-25 2023-09-28 Pharvaris Gmbh Composition solide comprenant des antagonistes du récepteur b2 de la bradykinine solubilisés
TW202345810A (zh) 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物
WO2023180577A1 (fr) 2022-03-25 2023-09-28 Pharvaris Gmbh Utilisations thérapeutiques d'antagonistes du récepteur b2 de la bradykinine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
AU8730691A (en) * 1990-09-28 1992-04-28 Neorx Corporation Polymeric carriers for release of covalently linked agents
WO1995004277A1 (fr) * 1993-08-03 1995-02-09 Sphinx Pharmaceuticals Corporation Methode de preparation et selection de composes non peptidiques a usage pharmacologique a partir d'une bibliotheque universelle d'elements de structures diverses

Also Published As

Publication number Publication date
WO1999064039A1 (fr) 1999-12-16
EP1085895A1 (fr) 2001-03-28
WO1999064039A9 (fr) 2000-10-12
AU4335299A (en) 1999-12-30
JP2002517461A (ja) 2002-06-18

Similar Documents

Publication Publication Date Title
US6288055B1 (en) Analgesic agents
US6693202B1 (en) Muscarinic receptor antagonists
US20020028943A1 (en) Multibinding inhibitors of microsomal triglyceride transferase protein
CA2320290A1 (fr) Inhibiteurs a liaisons multiples de cyclooxygenase-2
CA2319730A1 (fr) Antagonistes de bradykinine
US6593497B1 (en) β2-adrenergic receptor agonists
US6420560B1 (en) H1—histamine receptor antagonists
CA2321191A1 (fr) Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht3
ZA200004083B (en) H1-histamine receptor antagonists.

Legal Events

Date Code Title Description
FZDE Discontinued